Clinical Trial Update: A PHASE II PROSPECTIVE RANDOMIZED DOUBLE-MASKED CONTROLLED STUDY ASSESSING THE SAFETY & EFFICACY OF RHPRG4 (450 µG/ML RECOMBINANT HUMAN PROTEOGLYCAN 4) COMPARED TO VEHICLE FOR THE TREATMENT OF SJÖGREN'S RELATED DRY EYE DISEASE [Phase 2]

View source ↗

Summary

A Phase II randomized, double-masked trial is evaluating the safety and efficacy of rhPRG4 for Sjögren's-related dry eye disease and is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Sjögren Syndrome

Drugs mentioned

• RHPRG4

Snippet

Sponsor: Lubris Bio Pty Ltd | Conditions: Sjögren's Syndrome | Phase 2 | Status: RECRUITING